← Back to Search

Anti-infective agents

Intravenous Antibiotics for Bacteremia (GOAT Trial)

N/A

Recruiting

Led By Pranita D Tamma, MD, MHS

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 30

Awards & highlights

GOAT Trial Summary

This trial is testing whether switching from IV antibiotics to oral antibiotics early on is just as effective and safer for treating a type of bloodstream infection called Gram-Negative BloodStream Infection (GN-BSI

Who is the study for?

Adults over 18 with a Gram-negative bacterial infection in their bloodstream, who can give informed consent and are willing to follow the study procedures. Participants must be hospitalized and able to complete a quality of life interview.Check my eligibility

What is being tested?

The GOAT Trial is testing whether taking oral antibiotics at home is as effective and safer than staying on intravenous antibiotics for treating Gram-Negative Bloodstream Infections.See study design

What are the potential side effects?

Potential side effects may include allergic reactions, gastrointestinal issues like nausea or diarrhea, possible organ toxicity, and antibiotic resistance with both oral and IV antibiotics.

GOAT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 30

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Desirability of Outcome Ranking (DOOR)

Secondary outcome measures

Frequency of Recurrent infection

Incidence of All Cause Mortality

Length of stay (days)

+1 more

GOAT Trial Design

2Treatment groups

Active Control

Group I: Intravenous AntibioticsActive Control1 Intervention

IV antibiotics from the time of randomization to the completion of antibiotic treatment. Includes antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem.

Group II: Oral AntibioticsActive Control1 Intervention

Oral antibiotics from the time of randomization to the completion of antibiotic treatment, Includes antibiotics such as amoxicillin, cephalexin, ciprofloxacin, and trimethoprim-sulfamethoxazole.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,266 Previous Clinical Trials

14,836,293 Total Patients Enrolled

4 Trials studying Bacteremia

57,858 Patients Enrolled for Bacteremia

Patient-Centered Outcomes Research InstituteOTHER

551 Previous Clinical Trials

29,996,254 Total Patients Enrolled

1 Trials studying Bacteremia

610 Patients Enrolled for Bacteremia

Pranita D Tamma, MD, MHSPrincipal InvestigatorJohns Hopkins University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of individuals being admitted into this research investigation?

"Indeed, the information available on clinicaltrials.gov confirms that this investigation is actively seeking eligible individuals. Noted as being initially posted on February 22nd of the year 2024, with its latest update recorded on March 25th of the same year. This research endeavor aims to enroll a total of 1204 participants distributed across nine distinct locations."

Answered by AI

Are potential participants currently able to apply for enrollment in this ongoing clinical trial?

"Indeed, information available on clinicaltrials.gov indicates that this particular clinical trial is actively seeking subjects. Originally listed on February 22nd, 2024, the trial's most recent update was on March 25th of the same year. The study aims to enroll a total of 1204 participants across nine different locations."

Answered by AI

At how many distinct sites is this clinical trial being conducted?

"Nine institutions are participating in this research, including the University of California located in San Francisco, Denver Health Hospital Authority situated in Denver, and Mayo Clinic based in Rochester. Additionally, there are nine more sites involved across various regions."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

2024. "Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06080698.

All > Nashville > Sepsis